Cipher Submits Revised NDA for CIP-Tramadol ER
Posted on: Wednesday, 14 May 2008, 09:01 CDT
Cipher Pharmaceuticals has submitted a revised new drug application to the FDA for CIP-Tramadol ER, its extended-release formulation of tramadol.
The company's revised new drug application (NDA) includes data from additional pharmacokinetic studies conducted by the company comparing CIP-Tramadol ER to Ultram ER. Subject to FDA acceptance for filing, the company expects the review to be completed by October 2008.
After considering feedback from the FDA appeal process and the results of the additional statistical sensitivity analysis of existing data suggested by the FDA, the company and its advisors concluded that submitting the revised NDA provided the most expeditious path to final regulatory approval.
Source: Datamonitor
Related Articles
- Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin Alfa)
- FDA Extends Review of NDA for Entereg, Say Adolor and GSK
- FDA Extends Review of NDA for ENTEREG(R) (Alvimopan)
- Edwards Gets FDA Approval for Revised Heart Valve Trial
- FDA Issues Second Approvable Letter for Trexima(TM)
- Ortho Biotech Revises Prescribing Information for PROCRIT(R) (Epoetin Alfa)
- FDA Limits Use of Sanofi Antibiotic
- Labopharm Appeals FDA's Tramadol Decision
- Cumberland Pharmaceuticals Announces Updated Labeling for Acetadote(R)
- Labeling Revision for CRESTOR(R) Approved By FDA
 |
 |
User Comments (0)
RSS Feeds